Home > Journals > Minerva Biotechnology and Biomolecular Research > Past Issues > Minerva Biotecnologica 2020 December;32(4) > Minerva Biotecnologica 2020 December;32(4):139-42

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Biotecnologica 2020 December;32(4):139-42

DOI: 10.23736/S1120-4826.19.02598-9

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Predicted peptide-based MHC-I, MHC-II, CTL and B-cell epitopes of MUC-1 by immunoinformatics methods: a clue for novel multi-epitope vaccine development against breast cancer

Pejman HASHEMZADEH 1, Vajihe GHORBANZADEH 2, Hassan DARIUSHNEJAD 1, 2

1 Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran; 2 Razi Herbal Medicines Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran



BACKGROUND: Breast cancer (BC) is one of the most common types of women malignancy. Multi-epitope vaccines are new hopes for treatment of this cancer. MUC-1 is a tumor associated antigen that focused for multi-epitope vaccine development in case of BC.
METHODS: Here, primary data from a computation analysis of this glycoprotein to find potential MHC-I, MHC-II, CTL and B-cell epitopes are described using immunoinformatics tools.
RESULTS: According to the results, 1156VPGWGIALL984 corresponding to HLA-B0702 and HLA-A0101 alleles for MHC-I epitopes, 1209YPTYHTHGR1118 corresponding to DRB1*13 and DQB1*06 alleles for MHC-II epitops, 1122NQYKTEAAS45 for CTL epitopes and 1204HPMSEYPTYHTHGRYV896 for B-cell epitopes are the peptides with the best binding affinity.
CONCLUSIONS: These data may be useful for further multi-epitope vaccine development.


KEY WORDS: Breast neoplasms; Epitopes; Vaccines, synthetic; Mucin-1

top of page